Sviataslau Sasinovich

Dr. Sviataslau Sasinovich

Lund University, Lund, Sweden
orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 February 2022 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
STSara Thuresson
Sara Thuresson
CFCarl Johan Fraenkel
Carl Johan Fraenkel
SSSviataslau Sasinovich
Sviataslau Sasinovich
JSJonathan Soldemyr
Jonathan Soldemyr
AWAnders Widell
Anders Widell
JLJakob Löndahl
Jakob Löndahl
Transmission of coronavirus disease 2019 (COVID-19) can occur through inhalation of fine droplets or aerosols containing infectious virus. The objective of this study was to identify situations, patient characteristics, environmental parameters, and aerosol-generating procedures (AGPs) associated with airborne severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus. Air samples were collected near hospitalized COVID-19 patients and analyzed by RT-qPCR. Results were related to distance to the patient, most recent patient diagnostic PCR cycle threshold (Ct) value, room ventilation, and ongoing potential AGPs. In total, 310 air samples were collected; of these, 26 (8%) were positive for SARS-CoV-2. Of the 231 samples from patient rooms, 22 (10%) were positive for SARS-CoV-2. Positive air samples were associated with a low patient Ct value (OR, 5.0 for Ct 25; P = .01; 95% CI: 1.18–29.5) and a shorter physical distance to the patient (OR, 2.0 for every meter closer to the patient; P = .05; 95% CI: 1.0–3.8). A mobile HEPA-filtration unit in the room decreased the proportion of positive samples (OR, .3; P = .02; 95% CI: .12–.98). No association was observed between SARS-CoV-2–positive air samples and mechanical ventilation, high-flow nasal cannula, nebulizer treatment, or noninvasive ventilation. An association was found with positive expiratory pressure training (P < .01) and a trend towards an association for airway manipulation, including bronchoscopies and in- and extubations. Our results show that major risk factors for airborne SARS-CoV-2 include short physical distance, high patient viral load, and poor room ventilation. AGPs, as traditionally defined, seem to be of secondary importance.

30 March 2022 in Viruses
Verified
Journal Article
Open access
PDF file
DADawit Assefa Arimide
Dawit Assefa Arimide
ZSZsófia Ilona Szojka
Zsófia Ilona Szojka
KSKidist Shita
Kidist Shita
AWAtsbeha Gebreegziabxier Weldemariam
Atsbeha Gebreegziabxier Weldemariam
FDFekadu Adugna Dadi
Fekadu Adugna Dadi
PMPatrik Medstrand
Patrik Medstrand
Dolutegravir-based antiretroviral therapy (ART) has been scaled up in many developing countries, including Ethiopia. However, subtype-dependent polymorphic differences might influence the occurrence of HIV-drug-resistance mutations (HIVDRMs). We analyzed the prevalence of pre-treatment integrase strand transfer inhibitor (INSTI) HIVDRMs and naturally occurring polymorphisms (NOPs) of the integrase gene, using plasma samples collected as part of the national HIVDR survey in Ethiopia in 2017. We included a total of 460 HIV-1 integrase gene sequences from INSTI-naïve (n = 373 ART-naïve and n = 87 ART-experienced) patients. No dolutegravir-associated HIVDRMs were detected, regardless of previous exposure to ART. However, we found E92G in one ART-naïve patient specimen and accessory mutations in 20/460 (4.3%) of the specimens. Moreover, among the 288 integrase amino acid positions of the subtype C, 187/288 (64.9%) were conserved (<1.0% variability). Analysis of the genetic barrier showed that the Q148H/K/R dolutegravir resistance pathway was less selected in subtype C. Docking analysis of the dolutegravir showed that protease- and reverse-transcriptase-associated HIVDRMs did not affect the native structure of the HIV-1 integrase. Our results support the implementation of a wide scale-up of dolutegravir-based regimes. However, the detection of polymorphisms contributing to INSTI warrants the continuous surveillance of INSTI resistance.

20 October 2022 in Viruses
Verified
Journal Article
Open access
PDF file
UTUroosa Tariq
Uroosa Tariq
JNJamirah Nazziwa
Jamirah Nazziwa
SSSviataslau Sasinovich
Sviataslau Sasinovich
SSSharaf Ali Shah
Sharaf Ali Shah
SNSadaf Naeem
Sadaf Naeem
JEJoakim Esbjörnsson
Joakim Esbjörnsson
(1) Background: HIV-1 sub-subtype A1 is common in parts of Africa, Russia, former Soviet Union countries, and Eastern Europe. In Pakistan, sub-subtype A1 is the predominant HIV-1 subtype. Preliminary evidence suggests that distinct strains of HIV-1 sub-subtype A1 are circulating in Pakistan; however, an in-depth molecular phylogenetic characterization of HIV-1 sub-subtype A1 strains in Pakistan have not been presented. We performed a detailed characterization of the HIV-1 sub-subtype A1 epidemic in Pakistan using state-of-the-art molecular epidemiology and phylodynamics. (2) Methods: A total of 143 HIV-1 sub-subtype A1 gag sequences, including 61 sequences generated specifically for this study from PLHIVs part of our cohort, representing all sub-subtype A1 gag sequences from Pakistan, were analyzed. Maximum-likelihood phylogenetic cluster analysis was used to determine the relationship between Pakistani sub-subtype A1 strains and pandemic sub-subtype A1 strains. Furthermore, we used signature variation, charge distribution, selection pressures, and epitope prediction analyses to characterize variations unique to Pakistani HIV-1 strains and establish the association between signature variations and Gag epitope profile. (3) Results: The HIV-1 sub-subtype A1 sequences from Pakistan formed three main clusters: two that clustered with Kenyan sequences (7 and 10 sequences, respectively) and one that formed a Pakistan-specific cluster of 123 sequences that were much less related to other sub-subtype A1 sequences available in the database. The sequences in the Pakistan-specific cluster and the Kenyan reference strains exhibited several signature variations, especially at amino acid positions 312, 319, 331, 372, 373, 383, and 402. Structural protein modeling suggested that amino acid changes in these positions result in alterations of the Gag protein structure as well as in Gag-specific T-cell epitopes. (4) Conclusions: Our results suggest that the majority of the Pakistan HIV-1 sub-subtype A1 strains were unique to Pakistan and with a specific mutation pattern in Gag.

31 January 2025 in Viruses
Verified
Journal Article
Open access
PDF file
KSKidist Shita
Kidist Shita
AWAtsbeha Gebreegziabxier Weldemariam
Atsbeha Gebreegziabxier Weldemariam
YMYimam Getaneh Misganie
Yimam Getaneh Misganie
EKEleni Kidane
Eleni Kidane
BHBelete Hailemariam
Belete Hailemariam
DADawit Assefa Arimide
Dawit Assefa Arimide
HIV drug resistance (HIVDR) presents a significant challenge to antiretroviral therapy (ART) success, particularly in resource-limited settings like Ethiopia. This cross-sectional study investigated viral suppression rates and resistance patterns among patients on second-line ART across 28 Ethiopian health facilities. Blood samples collected from 586 participants were analyzed to measure CD4 count and viral load and assess HIVDR in patients experiencing virological failure (VF) (viral load ≥ 1000 copies/mL). Demographic and clinical data were analyzed using logistic regression to identify factors associated with VF. Results showed that 13.82% of participants experienced VF, with 67.57% of genotyped samples exhibiting at least one drug resistance mutation. Resistance to nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), and protease inhibitors (PIs) was detected in 48.64%, 64.86%, and 18.92% of cases, respectively. Dual-class resistance was identified in 48.64% of patients, while triple-class resistance was detected in 18.92%. VF was more likely among students and those with CD4 counts below 200 cells/mm³, but less likely in patients on second-line treatment for 12 months or more. Our findings highlight a substantial HIVDR burden among patients on second-line ART with VF, emphasizing the need for comprehensive HIV care, including adherence support, regular viral load monitoring, and HIVDR testing.

1 December 2011 in AIDS Research and Human Retroviruses
Verified
Journal Article
Closed access
VEVladimir F. Eremin
Vladimir F. Eremin
EGElena L. Gasich
Elena L. Gasich
SSSviataslau Sasinovich
Sviataslau Sasinovich
The new HIV-1 recombinant, with a B gag A pol A env structure, is described. This recombinant virus differs from the classical “Kaliningrad” (AF193276.1) virus with an A gag B pol B env structure. The number of new HIV cases in Belarus has been increasing in the past few years. Within the 12 months of 2010, 1069 new cases of HIV infection were registered. Molecular epidemiological investigations have shown that though HIV-1 subtype A (84.5%) still dominates in HIV/AIDS patients, the quantity of CRFs has also increased to 7.1%. Although cases with the CRF03_AB virus were previously described in patients from Belarus, CRF06_cpx and CRF02_AG are described in Belarus for the first time.

1 January 2024 in Indoor Air
Verified
Journal Article
Open access
PDF file
STSara Thuresson
Sara Thuresson
CFCarl-Johan Fraenkel
Carl-Johan Fraenkel
SSSviataslau Sasinovich
Sviataslau Sasinovich
PMPatrik Medstrand
Patrik Medstrand
MAMalin Alsved
Malin Alsved
JLJakob Löndahl
Jakob Löndahl
Background. Airborne SARS‐CoV‐2 plays a prominent role in COVID‐19 transmission. Numerous studies have sampled air from patient rooms, but airborne spread to other hospital areas such as corridors is less investigated. Methods. Size‐fractionated aerosol particles were collected weekly, with 12 hours of sampling time daily, in corridors at two infectious disease wards in southern Sweden between March 2020 and May 2021. Samples were analysed with real‐time reverse transcription polymerase chain reaction (RT‐qPCR) for detection of SARS‐CoV‐2 RNA. Indoor temperature, relative humidity, and CO2 concentration were monitored during the sampling period. Results. 20 of the 784 collected samples contained SARS‐CoV‐2 RNA, although in low concentrations. Positive air samples were found in sizes between 0.14 and 8.1 μm, but none >8.1 μm. 45% were found in submicron particles. No clear seasonal pattern was observed among the positive samples. There was no significant difference in the positivity rate of the samples between the two wards. Conclusions. SARS‐CoV‐2 was only detected in 2.6% of the aerosol samples, which indicates that the spread of airborne virus from patient rooms to the corridor was limited.